KemPharm Inc. (US4884452065)
XSTU 
Summary
US4884452065 Chart
Zevra Therapeutics Q2 Earnings Call Highlights
Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $1.21 per share a year ago.
KemPharm Inc. (US4884452065) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has KemPharm Inc. ever had a stock split?
KemPharm Inc. Profile
| Biotechnology Industry | Healthcare Sector | Neil F. McFarlane CEO | XSTU Exchange | US4884452065 ISIN |
| US Country | 61 Employees | - Last Dividend | 28 Dec 2020 Last Split | - IPO Date |
Overview
Zevra Therapeutics, Inc., initially known as KemPharm, Inc., rebranded itself in February 2023 and has established its operations in Celebration, Florida, since its inception in 2006. The company is at the forefront of discovering and developing a range of proprietary prodrugs aimed at treating severe medical conditions in the United States. Leveraging its Ligand Activated Therapy platform, Zevra Therapeutics strives to innovate in the pharmaceutical landscape by advancing its lead candidates and a diverse portfolio of drugs through clinical trials, targeting various disorders. Through strategic collaborations and licensing agreements with entities like Commave Therapeutics SA and Acer and Relief Therapeutics, Inc., Zevra Therapeutics is expanding its footprint in the development, manufacture, and commercialization of novel prodrugs.
Products and Services
- KP1077
A leading product candidate developed for the treatment of sleep disorders, KP1077 is undergoing rigorous testing. KP1077IH is in a Phase 2 clinical trial targeting idiopathic hypersomnia, a sleep disorder causing excessive daytime drowsiness. Concurrently, KP1077N is navigating through a Phase 1/2 clinical trial aimed at managing narcolepsy, a condition characterized by sudden sleep attacks.
- Celiprolol
A prodrug candidate, Celiprolol, is under Phase 1/2 clinical assessment for treating vascular Ehlers Danlos syndrome, a rare genetic disorder affecting the body's connective tissue. This pioneering treatment approach underscores Zevra's commitment to addressing complex, rare diseases through innovative therapies.
- AZSTARYS
This once-daily treatment is designed for patients aged six years and older struggling with attention deficit hyperactivity disorder (ADHD). AZSTARYS represents Zevra Therapeutics' strides towards providing relief and support to individuals and families affected by ADHD through advanced pharmaceutical solutions.
- OLPRUVA
Targeting urea cycle disorders, OLPRUVA is part of Zevra Therapeutics' portfolio aimed at treating metabolic diseases. By focusing on such disorders, the company illustrates its dedication to tackling less common but impactful health conditions with groundbreaking drug developments.
- Arimoclomol
Designed to combat niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder, Arimoclomol is a testament to Zevra Therapeutics' commitment to addressing neurodegenerative diseases through advanced therapeutic strategies. This initiative highlights the company's dedication to innovation and care for individuals battling severe, life-altering conditions.
